Nothing Special   »   [go: up one dir, main page]

CN111093706A - Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途 - Google Patents

Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途 Download PDF

Info

Publication number
CN111093706A
CN111093706A CN201880059076.8A CN201880059076A CN111093706A CN 111093706 A CN111093706 A CN 111093706A CN 201880059076 A CN201880059076 A CN 201880059076A CN 111093706 A CN111093706 A CN 111093706A
Authority
CN
China
Prior art keywords
inhibitor
use according
chemotherapy
vegfr
ribopolymerase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880059076.8A
Other languages
English (en)
Other versions
CN111093706B (zh
Inventor
王泉人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN202111060793.2A priority Critical patent/CN113768933B/zh
Publication of CN111093706A publication Critical patent/CN111093706A/zh
Application granted granted Critical
Publication of CN111093706B publication Critical patent/CN111093706B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明提供了PARP抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途。具体而言，本发明提供一种PARP抑制剂在制备治疗化疗耐药的卵巢癌或乳腺癌的药物中的用途，所述PARP抑制剂选自如通式(B)所示的化合物或其可药用的盐。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN201880059076.8A 2017-12-06 2018-12-05 Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途 Active CN111093706B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111060793.2A CN113768933B (zh) 2017-12-06 2018-12-05 Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711278350 2017-12-06
CN2017112783504 2017-12-06
PCT/CN2018/119318 WO2019109938A1 (zh) 2017-12-06 2018-12-05 Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111060793.2A Division CN113768933B (zh) 2017-12-06 2018-12-05 Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途

Publications (2)

Publication Number Publication Date
CN111093706A true CN111093706A (zh) 2020-05-01
CN111093706B CN111093706B (zh) 2022-06-21

Family

ID=66751288

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880059076.8A Active CN111093706B (zh) 2017-12-06 2018-12-05 Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途
CN202111060793.2A Active CN113768933B (zh) 2017-12-06 2018-12-05 Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111060793.2A Active CN113768933B (zh) 2017-12-06 2018-12-05 Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途

Country Status (11)

Country Link
US (1) US20200281923A1 (zh)
EP (1) EP3721906A4 (zh)
JP (1) JP2021505548A (zh)
KR (1) KR20200096788A (zh)
CN (2) CN111093706B (zh)
AU (1) AU2018380174A1 (zh)
BR (1) BR112020010435A2 (zh)
CA (1) CA3080644A1 (zh)
MX (1) MX2020005659A (zh)
TW (1) TW201924720A (zh)
WO (1) WO2019109938A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113874018A (zh) * 2019-05-28 2021-12-31 江苏恒瑞医药股份有限公司 Parp抑制剂联合vegfr抑制剂用于治疗卵巢癌或乳腺癌的用途
WO2022022541A1 (zh) * 2020-07-29 2022-02-03 深圳微芯生物科技股份有限公司 Rbm10基因的用途
CN115105599A (zh) * 2021-03-17 2022-09-27 四川大学 一种抗肿瘤的联合用药物及其应用
WO2024099387A1 (zh) * 2022-11-09 2024-05-16 同宜医药（苏州）有限公司 通过施用配体-药物偶联体治疗癌症

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020011848A (es) 2018-05-10 2021-03-29 Regeneron Pharma Formulaciones que contienen proteína de fusión del receptor de vegf a alta concentración.
JP2024518509A (ja) * 2021-05-18 2024-05-01 オンコニック セラピューティクス インコーポレイテッド Ｐａｒｐ阻害剤抵抗性癌治療剤
IL315159A (en) * 2022-02-24 2024-10-01 Akeso Pharmaceuticals Inc A pharmaceutical preparation containing a bispecific antibody of anti-4 CTLA anti-1-PD and CHIAURANIB

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307475A (zh) * 2009-02-04 2012-01-04 彼帕科学公司 用与生长因子抑制剂组合的parp抑制剂治疗肺癌
WO2012019427A1 (zh) * 2010-08-09 2012-02-16 上海恒瑞医药有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2018099423A1 (zh) * 2016-12-01 2018-06-07 江苏恒瑞医药股份有限公司 一种vegfr抑制剂与parp抑制剂联合在制备治疗胃癌的药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129252B2 (en) 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
CN101676267B (zh) 2008-09-16 2012-12-26 江苏恒瑞医药股份有限公司 N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐
US20120039805A1 (en) 2009-02-20 2012-02-16 Pangea Biosciences, Inc. Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample
AU2013280644B2 (en) 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2016116602A1 (en) 2015-01-23 2016-07-28 Astrazeneca Ab Treatment of cancer
US9751859B2 (en) 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
SG11202002499TA (en) * 2017-10-06 2020-04-29 Tesaro Inc Combination therapies and uses thereof
CN111918667A (zh) * 2018-02-05 2020-11-10 特沙诺有限公司 儿科尼拉帕尼配制剂和儿科治疗方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307475A (zh) * 2009-02-04 2012-01-04 彼帕科学公司 用与生长因子抑制剂组合的parp抑制剂治疗肺癌
WO2012019427A1 (zh) * 2010-08-09 2012-02-16 上海恒瑞医药有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2018099423A1 (zh) * 2016-12-01 2018-06-07 江苏恒瑞医药股份有限公司 一种vegfr抑制剂与parp抑制剂联合在制备治疗胃癌的药物中的用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JOYCE F LIU 等.: "Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.", 《ONCOLOGY》 *
JOYCE F. LIU 等: "A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.", 《EUROPEAN JOURNAL OF CANCER》 *
冯久桓 等.: "甲磺酸阿帕替尼的研究现状与进展.", 《临床肿瘤学杂志》 *
李玲 等.: "阿帕替尼治疗难治性恶性肿瘤43例疗效观察.", 《中华实用诊断与治疗杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113874018A (zh) * 2019-05-28 2021-12-31 江苏恒瑞医药股份有限公司 Parp抑制剂联合vegfr抑制剂用于治疗卵巢癌或乳腺癌的用途
WO2022022541A1 (zh) * 2020-07-29 2022-02-03 深圳微芯生物科技股份有限公司 Rbm10基因的用途
CN115105599A (zh) * 2021-03-17 2022-09-27 四川大学 一种抗肿瘤的联合用药物及其应用
WO2024099387A1 (zh) * 2022-11-09 2024-05-16 同宜医药（苏州）有限公司 通过施用配体-药物偶联体治疗癌症

Also Published As

Publication number Publication date
TW201924720A (zh) 2019-07-01
CA3080644A1 (en) 2019-06-13
US20200281923A1 (en) 2020-09-10
AU2018380174A1 (en) 2020-05-21
CN113768933B (zh) 2024-02-20
JP2021505548A (ja) 2021-02-18
RU2020119898A (ru) 2022-01-10
CN111093706B (zh) 2022-06-21
CN113768933A (zh) 2021-12-10
BR112020010435A2 (pt) 2020-11-24
KR20200096788A (ko) 2020-08-13
EP3721906A1 (en) 2020-10-14
EP3721906A4 (en) 2021-08-04
WO2019109938A1 (zh) 2019-06-13
RU2020119898A3 (zh) 2022-01-19
MX2020005659A (es) 2020-08-20

Similar Documents

Publication Publication Date Title
CN111093706B (zh) Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途
WO2021063332A1 (zh) 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途
CN111728974B (zh) 西奥罗尼用于小细胞肺癌的治疗
WO2018099423A1 (zh) 一种vegfr抑制剂与parp抑制剂联合在制备治疗胃癌的药物中的用途
CN112870367A (zh) Ezh2抑制剂、cdk4/6抑制剂和mek抑制剂在制备治疗肿瘤药物中的用途
CN113840608A (zh) Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途
WO2020238932A1 (zh) Parp抑制剂联合vegfr抑制剂用于治疗卵巢癌或乳腺癌的用途
JP7381115B2 (ja) 組成物及びがん治療用医薬品の調製におけるその応用
CN112870365A (zh) Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途
CN112543646B (zh) 一种抗pd-1抗体和法米替尼联合在制备治疗肿瘤的药物中的用途
CN110680919A (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗肿瘤的药物的用途
JP2022542725A (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
CN112584836A (zh) 一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途
WO2023030437A1 (zh) 一种pi3k抑制剂与btk抑制剂在制备治疗淋巴瘤的药物中的用途
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
WO2023284790A1 (zh) 选择性雌激素受体共价拮抗剂与cdk4/6抑制剂联合在制备治疗乳腺癌药物中的用途
WO2023051606A1 (zh) Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途
WO2022199656A1 (zh) 药物组合、包含其的试剂盒及其用途
CN115444938A (zh) cGAS抑制剂与化疗药物联合在制备治疗肺癌药物中的用途
CN118613259A (zh) 用于治疗实体瘤的口服施用紫杉醇、P-gp抑制剂和检查点抑制剂的治疗组合
WO2024120483A1 (zh) 喹诺林化合物治疗卵巢癌的用途
CN114761010A (zh) 喹唑啉衍生物或其盐的联用药物组合物及其用途
JP2019511547A (ja) 結腸直腸癌を治療するためのニンテダニブ、トリフルリジンおよびチピラシルの医薬組合せ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40025353

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant